Table 1 Characteristics and laboratory findings of patients with COVID-19.
From: Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19
|  | Mild cases, n = 8 | Severe cases, n = 7 | P-value |
|---|---|---|---|
Characteristics | |||
Age, years | 51.3 (26–97) | 62 (36–78) | 0.1787 |
Male | 6 (75) | 4 (57) | 0.6084 |
Body mass index, kg/m2 | 22.3 (11.8–26.6) | 23.3 (20.3–27.7) | > 0.9999 |
Fever | 1 (12.5) | 6 (85.7) | 0.0101 |
Sampling point from symptom onset (day) | 6.9 (5–10) | 7.6 (5–11) | 0.5859 |
Mechanical ventilator use | 0 (0) | 7 (100) | 0.0002 |
Modified Early Warning Score (MEWS) | 1.3 (1–2) | 2.6 (2–3) | 0.0023 |
National Early Warning Score (NEWS) | 0.1 (0–1) | 5 (1–8) | 0.0005 |
Sequential Organ Failure Assessment (SOFA) score | 0.1 (0–1) | 2.7 (0–6) | 0.0039 |
Underlying conditions | |||
Cardiovascular disease | 0 (0) | 0 (0) | > 0.9999 |
Cerebrovascular disease | 0 (0) | 0 (0) | > 0.9999 |
Diabetes mellitus | 0 (0) | 1 (14.3) | 0.4667 |
Chronic kidney disease | 0 (0) | 1 (14.3) | 0.4667 |
Charlson Comorbidity Index (CCI) | 1.3 (0–5) | 3.1 (0–6) | 0.0847 |
Laboratory findings | |||
White blood cell count, × 103/mm3 | 4.3 (3.7–5.5) | 6.3 (2.8–11.8) | 0.267 |
Neutrophil, × 103/mm3 | 2.8 (1.9–3.6) | 4.7 (2.1–10.4) | 0.1206 |
Lymphocyte, × 103/mm3 | 1.1 (0.5–1.9) | 1.1 (0.6–1.9) | 0.8665 |
Neutrophil-to-lymphocyte ratio | 3.1 (1.1–5.8) | 4.8 (2.5–11.0) | 0.1893 |
Monocyte, × 103/mm3 | 0.4 (0.2–0.6) | 0.5 (0.1–0.9) | 0.4129 |
Monocyte, % | 8.4 (5.8–13.0) | 7.8 (3.1–14.3) | 0.8665 |
Platelet, × 103/mm3 | 192.8 (107–314) | 187.7 (97–269) | > 0.9999 |
Alanine aminotransferase, U/L | 37.8 (12–121) | 23.9 (8–53) | 0.9282 |
Aspartate aminotransferase, U/L | 27.1 (13–50) | 41.6 (19–110) | 0.2922 |
Albumin, g/dL | 4.1 (3.4–4.6) | 3.0 (2.3–4.1) | 0.0068 |
Total bilirubin, mg/dL | 0.6 (0.1–1.9) | 0.7 (0.1–2.27) | 0.4834 |
Lactate dehydrogenase, U/L | 404.4 (280–554) | 701.3 (340–1461) | 0.0541 |
C-reactive protein, mg/dL | 0.7 (0.3–1.7) | 8.1 (2.3–12.4) | 0.0003 |
